Full-Time

Senior Director

Global Medical Strategy, Pancreatic Cancer

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$240k - $286kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • An advanced doctorate degree (PharmD, PhD, MD, DO or equivalent) in medical/scientific area is required.
  • Ten years minimum experience in academic medicine, biotech and/or pharmaceutical industry, with at least five years of experience in oncology research and/or patient care.
  • Must have a strong scientific background in oncology with good understanding of biomarker-driven disease and ability to effectively analyze, synthesize, and communicate complex scientific information.
  • Strong networking skills with deep existing relationships with oncology healthcare professionals including global top key opinion leaders required.
  • Experience in KOL mapping and development of engagement plans required.
  • Previous overall responsibility and accountability for medical affairs activities, including budget management for more than one compound (pipeline and marketed).
  • Direct, hands-on experience executing the activities of various functions within medical affairs (training, medical communications, medical information, EAP, Evidence Generation, publications).
  • Extensive experience in global product launches including support of integrated brand plan ideation, regulatory submissions, reimbursement, and label development.
  • Proven track record of clinical trial support including protocol development/review, site selection support, enrollment support, and data analysis.
  • Experience conducting gap assessments and executing evidence generation plans including the developing and running of medical affairs company sponsored studies (MACS), ISRs, and Health Economics and Outcomes Research (HEOR) projects.
  • Excellent verbal, written, and presentation skills with the ability to effectively communicate complex scientific data to diverse audiences.
  • Thrives in fast-paced, dynamic environment and can manage multiple priorities at one time with little direction.
  • Ability to travel to Redwood City headquarters and professional congresses (30-40%).
  • Manage and adhere to RevMed policies, ensuring compliance with corporate rules and government regulations.
  • Commitment to RevMed Core Values.
Responsibilities
  • Support the development and execution of the multi-year global and US medical strategy for PDAC, including oversight of the publication and medical communications strategy, integrated evidence planning, lifecycle management and budget planning process.
  • Support development and execution of the GMA PDAC strategy and medical objectives including activities related to scientific engagement and communication, evidence generation, internal education, and patient advocacy.
  • Lead integrated evidence generation planning in PDAC including conducting routine cross-functional gap assessments leading to the development/refinement of a publication strategy, an evidence generation plan, and tactical plan as part of the overall GMA plan.
  • Provide medical leadership in scientific engagement activities with key external stakeholders through organizing and leading PDAC advisory boards, study investigator interactions, congress activities, and peer-to-peer discussions with the goal of communicating scientific insights to internal teams to drive strategy.
  • Serve as a senior medical leader communicating clinical and scientific data to physicians and other healthcare professionals through presentations, educational programs, and scientific discussions.
  • Support medical contribution to cross-functional strategy team meetings including Clinical and Safety sub-teams, product team, Market Access, commercial and other cross-functional strategic discussions.
  • Work closely with the Clinical and MSL teams to provide enrollment, scientific, and engagement support to ensure clinical trials meet study timelines.
  • Partner with RWE strategy and translational teams on related integrated evidence generation strategies and activities as part of the GMA Plan.
  • Partner with Patient Advocacy to incorporate the patient voice and define external medical education strategies for independent grants, respectively.
  • Support competitive intelligence team activities through landscape assessments, development of patient journey, and congress insights.
  • Provide medical support for scientific symposia and medical congresses and collaborate across GMA functions to develop, review, and align on key scientific communication points and medical information response documents within legal and compliance guidelines.
  • Support the review and approval of abstracts, manuscripts, corporate communications, and other documents as well as internal stakeholder medical education activities related to the compound data and related competitor data.
  • Provide medical strategy leadership for expanded access programs (EAP) and investigator sponsored research (ISR) for PDAC.
  • Manage budgets and resources efficiently for GMA supported activities in PDAC to maximize RevMed resources.
  • Adhere to Revolution Medicines Core Values and policies.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?